3 Clinical Trials for Various Conditions
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.
This real-world, observational registry captures structured data on chronic wounds and ulcers from 1,482 practitioners across all 50 U.S. states and Puerto Rico. Data are collected at the point of care through electronic health records (EHRs) or electronic data capture (EDC) systems and transmitted daily to the U.S. Wound Registry (USWR), a CMS-recognized Qualified Clinical Data Registry (QCDR). The registry supports quality improvement and comparative effectiveness research by providing insight into patient demographics, treatment patterns, and outcomes across a wide range of wound types and interventions.
This study will investigate how well Carbon Acetate PET/CT imaging helps to correctly identify recurrent tumor versus post treatment effects (radionecrosis) in patients with previously treated high grade brain gliomas.